====== Targeted therapy in low-grade glioma ======

see [[Targeted therapy for pediatric low-grade glioma]]
----

Liu Z, Cheng X, Pang B, Wang S, Liu B, Cao C, Qian R, Liang W, Zhu Y, Li P,
Gao Y. Effects of [[ESCO2]] or its methylation on the prognosis, clinical
characteristics, immune microenvironment, and pathogenesis of [[low-grade glioma]].
Int Immunopharmacol. 2022 Jan 7;104:108399. doi: 10.1016/j.intimp.2021.108399.
Epub ahead of print. PMID: 35008004.

2: Liu Z, Ren Z, Zhang C, Qian R, Wang H, Wang J, Zhang W, Liu B, Lian X, Wang
Y, Guo Y, Gao Y. [[ELK3]]: A New Molecular Marker for the Diagnosis and
Prognosis of Glioma. Front Oncol. 2021 Dec 16;11:608748. doi:
10.3389/fonc.2021.608748. PMID: 34976781; PMCID: PMC8716454.

3: Howden K, Chapman S, Serletis D, Kazina C, Rafay MF, Faury D, Hazrati LN,
Jabado N, Vanan MI. Management of Inoperable Supra-Sellar Low-Grade Glioma With
BRAF Mutation in Young Children. Cureus. 2021 Nov 9;13(11):e19400. doi:
10.7759/cureus.19400. PMID: 34926002; PMCID: PMC8656291.

4: Noor H, Zaman A, Teo C, Sughrue ME. [[PODNL1]] Methylation Serves as a
Prognostic Biomarker and Associates with Immune Cell Infiltration and Immune
Checkpoint Blockade Response in Lower-Grade Glioma. Int J Mol Sci. 2021 Nov
22;22(22):12572. doi: 10.3390/ijms222212572. PMID: 34830454; PMCID: PMC8625785.

5: Chen R, Wang X, Dai Z, Wang Z, Wu W, Hu Z, Zhang X, Liu Z, Zhang H, Cheng Q.
[[TNFSF13]] Is a Novel Onco-Inflammatory Marker and Correlates With Immune
Infiltration in Gliomas. Front Immunol. 2021 Oct 12;12:713757. doi:
10.3389/fimmu.2021.713757. PMID: 34712225; PMCID: PMC8546343.

6: Zimu Z, Jia Z, Xian F, Rui M, Yuting R, Yuan W, Tianhong W, Mian M, Yinlong
L, Enfang S. Decreased Expression of [[PACSIN1]] in Brain Glioma Samples Predicts
Poor Prognosis. Front Mol Biosci. 2021 Aug 5;8:696072. doi:
10.3389/fmolb.2021.696072. PMID: 34422904; PMCID: PMC8375027.

7: Lin Z, Wen M, Yu E, Lin X, Wang H, Chen J, Yao C, Zhang H, Ru J, Wang K,
Zhang Y, Huang L, Zhuge Q, Yang S. [[ANXA1]] as a Prognostic and Immune
Microenvironmental Marker for Gliomas Based on Transcriptomic Analysis and
Experimental Validation. Front Cell Dev Biol. 2021 Aug 4;9:659080. doi:
10.3389/fcell.2021.659080. PMID: 34422796; PMCID: PMC8371204.

8: Vlachos N, Lampros MG, Zigouris A, Voulgaris S, Alexiou GA. Anaplastic
gangliogliomas of the spinal cord: a scoping review of the literature. Neurosurg
Rev. 2021 Jul 27. doi: 10.1007/s10143-021-01612-3. Epub ahead of print. PMID:
34312775.

9: Wang Z, Chen X, Liang Q, An Y, Wei M, Shi W. Inhibiting of circ-TLK1 inhibits
the progression of glioma through down-regulating PANX1 via targeting miR-17-5p.
J Mol Histol. 2021 Oct;52(5):1007-1020. doi: 10.1007/s10735-021-09993-x. Epub
2021 Jun 28. PMID: 34181173.

10: Deng T, Gong Y, Liao X, Wang X, Zhou X, Zhu G, Mo L. Integrative Analysis of
a Novel Eleven-Small Nucleolar RNA Prognostic Signature in Patients With Lower
Grade Glioma. Front Oncol. 2021 Jun 7;11:650828. doi: 10.3389/fonc.2021.650828.
PMID: 34164339; PMCID: PMC8215672.

11: Sarma S, Khonglah Y, Mishra J, Kakati A, Phukan P. Gliomas - An experience
based on molecular markers. J Family Med Prim Care. 2021 Mar;10(3):1341-1346.
doi: 10.4103/jfmpc.jfmpc_1963_20. Epub 2021 Apr 8. PMID: 34041176; PMCID:
PMC8140246.

12: Jiang Y, Wang Z, Ying C, Hu J, Zeng T, Gao L.
FMR1/circCHAF1A/miR-211-5p/HOXC8 feedback loop regulates proliferation and
tumorigenesis via MDM2-dependent p53 signaling in GSCs. Oncogene. 2021
Jun;40(24):4094-4110. doi: 10.1038/s41388-021-01833-2. Epub 2021 May 20. PMID:
34017077.

13: Jünger ST, Timmermann B, Pietsch T. Pediatric ependymoma: an overview of a
complex disease. Childs Nerv Syst. 2021 Aug;37(8):2451-2463. doi:
10.1007/s00381-021-05207-7. Epub 2021 May 18. PMID: 34008056; PMCID: PMC8342354.

14: Zhu Z, Zhang X, Yu Z, Zhou Y, Zhu S, Zhang YH, Lin XP, Mou Y, Zhang J.
Correlation of Tim-3 expression with chemokine levels for predicting the
prognosis of patients with glioblastoma. J Neuroimmunol. 2021 Jun 15;355:577575.
doi: 10.1016/j.jneuroim.2021.577575. Epub 2021 Apr 20. PMID: 33901809.

15: Peeters SM, Muftuoglu Y, Na B, Daniels DJ, Wang AC. Pediatric Gliomas:
Molecular Landscape and Emerging Targets. Neurosurg Clin N Am. 2021
Apr;32(2):181-190. doi: 10.1016/j.nec.2020.12.001. Epub 2021 Feb 18. PMID:
33781501.

16: Yang J, Yang Q. Identification of Core Genes and Screening of Potential
Targets in Glioblastoma Multiforme by Integrated Bioinformatic Analysis. Front
Oncol. 2021 Feb 24;10:615976. doi: 10.3389/fonc.2020.615976. PMID: 33718116;
PMCID: PMC7943725.

17: Li X, Meng Y. Expression and prognostic characteristics of m<sup>5</sup> C
regulators in low-grade glioma. J Cell Mol Med. 2021 Feb;25(3):1383-1393. doi:
10.1111/jcmm.16221. Epub 2021 Jan 5. PMID: 33400376; PMCID: PMC7875931.

18: Qi Y, Liu B, Sun Q, Xiong X, Chen Q. Immune Checkpoint Targeted Therapy in
Glioma: Status and Hopes. Front Immunol. 2020 Nov 27;11:578877. doi:
10.3389/fimmu.2020.578877. PMID: 33329549; PMCID: PMC7729019.

19: Lombardi G, Barresi V, Castellano A, Tabouret E, Pasqualetti F, Salvalaggio
A, Cerretti G, Caccese M, Padovan M, Zagonel V, Ius T. Clinical Management of
Diffuse Low-Grade Gliomas. Cancers (Basel). 2020 Oct 16;12(10):3008. doi:
10.3390/cancers12103008. PMID: 33081358; PMCID: PMC7603014.

20: Wang J, Zhang Y, You A, Li J, Gu J, Rao G, Ge X, Zhang K, Fu H, Liu X, Li J,
Wang Q, Wu X, Cheng L, Zhu M, Wang D. HAS2-AS1 Acts as a Molecular Sponge for
miR-137 and Promotes the Invasion and Migration of Glioma Cells by Targeting
EZH2. Cell Cycle. 2020 Nov;19(21):2826-2835. doi: 10.1080/15384101.2020.1826237.
Epub 2020 Oct 16. PMID: 33064966; PMCID: PMC7714441.

21: Szalontay L, Khakoo Y. Medulloblastoma: an Old Diagnosis with New Promises.
Curr Oncol Rep. 2020 Jul 9;22(9):90. doi: 10.1007/s11912-020-00953-4. PMID:
32643099.

22: Miklja Z, Yadav VN, Cartaxo RT, Siada R, Thomas CC, Cummings JR, Mullan B,
Stallard S, Paul A, Bruzek AK, Wierzbicki K, Yang T, Garcia T, Wolfe I, Leonard
M, Robertson PL, Garton HJ, Wahl DR, Parmar H, Sarkaria JN, Kline C, Mueller S,
Nicolaides T, Glasser C, Leary SE, Venneti S, Kumar-Sinha C, Chinnaiyan AM, Mody
R, Pai MP, Phoenix TN, Marini BL, Koschmann C. Everolimus improves the efficacy
of dasatinib in PDGFRα-driven glioma. J Clin Invest. 2020 Oct
1;130(10):5313-5325. doi: 10.1172/JCI133310. PMID: 32603316; PMCID: PMC7524471.

23: Ma Q, Wang X, Wang H, Song W, Wang Q, Wang J. HMGN5 Silencing Suppresses
Cell Biological Progression via AKT/MAPK Pathway in Human Glioblastoma Cells.
Biomed Res Int. 2020 May 21;2020:8610271. doi: 10.1155/2020/8610271. PMID:
32596388; PMCID: PMC7273445.

24: Young JS, Gogos AJ, Morshed RA, Hervey-Jumper SL, Berger MS. Molecular
characteristics of diffuse lower grade gliomas: what neurosurgeons need to know.
Acta Neurochir (Wien). 2020 Aug;162(8):1929-1939. doi:
10.1007/s00701-020-04426-2. Epub 2020 May 30. PMID: 32472378.

25: Collins KL, Pollack IF. Pediatric Low-Grade Gliomas. Cancers (Basel). 2020
May 4;12(5):1152. doi: 10.3390/cancers12051152. PMID: 32375301; PMCID:
PMC7281318.

26: Wang Y, Zhao B, Chen W, Liu L, Chen W, Zhou L, Kong Z, Dai C, Wang Y, Ma W.
Pretreatment Geriatric Assessments of Elderly Patients with Glioma: Development
and Implications. Aging Dis. 2020 Mar 9;11(2):448-461. doi:
10.14336/AD.2019.0527. PMID: 32257553; PMCID: PMC7069455.

27: Cooney T, Yeo KK, Kline C, Prados M, Haas-Kogan D, Chi S, Mueller S. Neuro-
Oncology Practice Clinical Debate: targeted therapy vs conventional chemotherapy
in pediatric low-grade glioma. Neurooncol Pract. 2020 Jan;7(1):4-10. doi:
10.1093/nop/npz033. Epub 2019 Aug 13. PMID: 32257279; PMCID: PMC7104878.

28: Packer RJ, Iavarone A, Jones DTW, Blakeley JO, Bouffet E, Fisher MJ, Hwang
E, Hawkins C, Kilburn L, MacDonald T, Pfister SM, Rood B, Rodriguez FJ, Tabori
U, Ramaswamy V, Zhu Y, Fangusaro J, Johnston SA, Gutmann DH. Implications of new
understandings of gliomas in children and adults with NF1: report of a consensus
conference. Neuro Oncol. 2020 Jun 9;22(6):773-784. doi: 10.1093/neuonc/noaa036.
PMID: 32055852; PMCID: PMC7283027.

29: Tabibkhooei A, Izadpanahi M, Arab A, Zare-Mirzaei A, Minaeian S, Rostami A,
Mohsenian A. Profiling of novel circulating microRNAs as a non-invasive
biomarker in diagnosis and follow-up of high and low-grade gliomas. Clin Neurol
Neurosurg. 2020 Mar;190:105652. doi: 10.1016/j.clineuro.2019.105652. Epub 2019
Dec 27. PMID: 31896490.

30: Liu QJ, Lv JX, Liu J, Zhang XB, Wang LB. Nucleobindin-2 Promotes the Growth
and Invasion of Glioblastoma. Cancer Biother Radiopharm. 2019 Nov;34(9):581-588.
doi: 10.1089/cbr.2019.2829. PMID: 31697592.

31: Chen W, Lei C, Liu P, Liu Y, Guo X, Kong Z, Wang Y, Dai C, Wang Y, Ma W,
Wang Y. Progress and Prospects of Recurrent Glioma: A Recent Scientometric
Analysis of the Web of Science in 2019. World Neurosurg. 2020 Feb;134:e387-e399.
doi: 10.1016/j.wneu.2019.10.078. Epub 2019 Oct 19. PMID: 31639500.

32: Laviv Y. [DIFFUSE Low-grade glioma: PERSONALIZED ADAPTATION OF SURGICAL
RESECTION IN AN ERA OF TARGETED ONCOLOGICAL THERAPY]. Harefuah. 2019
Sep;158(9):601-606. Hebrew. PMID: 31507113.

33: Yin Y, Li B, Mou K, Khan MT, Kaushik AC, Wei D, Zhang YJ. Stoichioproteomics
reveal oxygen usage bias, key proteins and pathways in glioma. BMC Med Genomics.
2019 Aug 29;12(1):125. doi: 10.1186/s12920-019-0571-y. PMID: 31464612; PMCID:
PMC6716898.

34: Otani Y, Ichikawa T, Kurozumi K, Date I. Dynamic Reorganization of
Microtubule and Glioma Invasion. Acta Med Okayama. 2019 Aug;73(4):285-297. doi:
10.18926/AMO/56930. PMID: 31439951.

35: Tan MSY, Sandanaraj E, Chong YK, Lim SW, Koh LWH, Ng WH, Tan NS, Tan P, Ang
BT, Tang C. A STAT3-based gene signature stratifies glioma patients for targeted
therapy. Nat Commun. 2019 Aug 9;10(1):3601. doi: 10.1038/s41467-019-11614-x.
PMID: 31399589; PMCID: PMC6689009.

36: Liu J, Liu D, Yang Z, Yang Z. High LAMC1 expression in glioma is associated
with poor prognosis. Onco Targets Ther. 2019 May 29;12:4253-4260. doi:
10.2147/OTT.S205333. PMID: 31213842; PMCID: PMC6549796.

37: Park AK, Lee JY, Cheong H, Ramaswamy V, Park SH, Kool M, Phi JH, Choi SA,
Cavalli F, Taylor MD, Kim SK. Subgroup-specific prognostic signaling and
metabolic pathways in pediatric medulloblastoma. BMC Cancer. 2019 Jun
11;19(1):571. doi: 10.1186/s12885-019-5742-x. PMID: 31185958; PMCID: PMC6560914.

38: Erel-Akbaba G, Carvalho LA, Tian T, Zinter M, Akbaba H, Obeid PJ, Chiocca
EA, Weissleder R, Kantarci AG, Tannous BA. Radiation-Induced Targeted
Nanoparticle-Based Gene Delivery for Brain Tumor Therapy. ACS Nano. 2019 Apr
23;13(4):4028-4040. doi: 10.1021/acsnano.8b08177. Epub 2019 Mar 27. PMID:
30916923; PMCID: PMC7104714.

39: Wang X, Guo G, Guan H, Yu Y, Lu J, Yu J. Challenges and potential of
PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma. J Exp Clin Cancer
Res. 2019 Feb 18;38(1):87. doi: 10.1186/s13046-019-1085-3. PMID: 30777100;
PMCID: PMC6380009.

40: Sala L, Cirillo G, Riva G, Romano G, Giussani C, Cialdella A, Todisco A,
Virtuoso A, Cerrito MG, Bentivegna A, Grassilli E, Ardizzoia A, Bonoldi E,
Giovannoni R, Papa M, Lavitrano M. Specific Expression of a New Bruton Tyrosine
Kinase Isoform (p65BTK) in the Glioblastoma Gemistocytic Histotype. Front Mol
Neurosci. 2019 Jan 24;12:2. doi: 10.3389/fnmol.2019.00002. PMID: 30733667;
PMCID: PMC6353843.

41: Sarkiss CA, Germano IM. Machine Learning in Neuro-Oncology: Can Data
Analysis from 5,346 Patients Change Decision Making Paradigms? World Neurosurg.
2019 Jan 23:S1878-8750(19)30141-X. doi: 10.1016/j.wneu.2019.01.046. Epub ahead
of print. PMID: 30684706.

42: Chen CH, Chen PY, Lin YY, Feng LY, Chen SH, Chen CY, Huang YC, Huang CY,
Jung SM, Chen LY, Wei KC. Suppression of tumor growth via IGFBP3 depletion as a
potential treatment in glioma. J Neurosurg. 2019 Jan 11;132(1):168-179. doi:
10.3171/2018.8.JNS181217. PMID: 30641835.

43: D'Alessandris QG, Montano N, Martini M, Cenci T, Lauretti L, Stumpo V,
Pignotti F, Olivi A, Fernandez E, Larocca LM, Pallini R. Eight-year survival of
a Glioblastoma recurrence patient treated with molecularly tailored therapy: a
case report. Acta Neurochir (Wien). 2018 Dec;160(12):2387-2391. doi:
10.1007/s00701-018-3697-3. Epub 2018 Oct 11. PMID: 30306271.

44: Hashimoto Y, Penas-Prado M, Zhou S, Wei J, Khatua S, Hodges TR, Sanai N, Xiu
J, Gatalica Z, Kim L, Kesari S, Rao G, Spetzler D, Heimberger A. Rethinking
medulloblastoma from a targeted therapeutics perspective. J Neurooncol. 2018
Sep;139(3):713-720. doi: 10.1007/s11060-018-2917-2. Epub 2018 Jun 5. PMID:
29869738; PMCID: PMC6132970.

45: Miller KE, Kelly B, Fitch J, Ross N, Avenarius MR, Varga E, Koboldt DC, Boué
DR, Magrini V, Coven SL, Finlay JL, Cottrell CE, White P, Gastier-Foster JM,
Wilson RK, Leonard J, Mardis ER. Genome sequencing identifies somatic
<i>BRAF</i> duplication c.1794_1796dupTAC;p.Thr599dup in pediatric patient with
low-grade ganglioglioma. Cold Spring Harb Mol Case Stud. 2018 Apr
2;4(2):a002618. doi: 10.1101/mcs.a002618. PMID: 29434027; PMCID: PMC5880266.

46: Wagner LM, Myseros JS, Lukins DE, Willen CM, Packer RJ. Targeted therapy for
infants with diencephalic syndrome: A case report and review of management
strategies. Pediatr Blood Cancer. 2018 May;65(5):e26917. doi: 10.1002/pbc.26917.
Epub 2018 Jan 25. PMID: 29369501.

47: Dong Y, Furuta T, Sabit H, Kitabayashi T, Jiapaer S, Kobayashi M, Ino Y,
Todo T, Teng L, Hirao A, Zhao SG, Nakada M. Identification of antipsychotic drug
fluspirilene as a potential anti-glioma stem cell drug. Oncotarget. 2017 Dec
4;8(67):111728-111741. doi: 10.18632/oncotarget.22904. PMID: 29340087; PMCID:
PMC5762355.

48: Jones DTW, Kieran MW, Bouffet E, Alexandrescu S, Bandopadhayay P, Bornhorst
M, Ellison D, Fangusaro J, Fisher MJ, Foreman N, Fouladi M, Hargrave D, Hawkins
C, Jabado N, Massimino M, Mueller S, Perilongo G, Schouten van Meeteren AYN,
Tabori U, Warren K, Waanders AJ, Walker D, Weiss W, Witt O, Wright K, Zhu Y,
Bowers DC, Pfister SM, Packer RJ. Pediatric low-grade gliomas: next biologically
driven steps. Neuro Oncol. 2018 Jan 22;20(2):160-173. doi:
10.1093/neuonc/nox141. Erratum in: Neuro Oncol. 2018 Jan 22;20(2):293. PMID:
29016845; PMCID: PMC5786244.

49: Zhu P, Zhu JJ. Tumor treating fields: a novel and effective therapy for
glioblastoma: mechanism, efficacy, safety and future perspectives. Chin Clin
Oncol. 2017 Aug;6(4):41. doi: 10.21037/cco.2017.06.29. PMID: 28841803.

50: Jain P, Fierst TM, Han HJ, Smith TE, Vakil A, Storm PB, Resnick AC, Waanders
AJ. CRAF gene fusions in pediatric low-grade gliomas define a distinct drug
response based on dimerization profiles. Oncogene. 2017 Nov 9;36(45):6348-6358.
doi: 10.1038/onc.2017.276. Epub 2017 Aug 14. PMID: 28806393; PMCID: PMC5680138.

51: Furuta T, Sabit H, Dong Y, Miyashita K, Kinoshita M, Uchiyama N, Hayashi Y,
Hayashi Y, Minamoto T, Nakada M. Biological basis and clinical study of glycogen
synthase kinase- 3β-targeted therapy by drug repositioning for glioblastoma.
Oncotarget. 2017 Apr 4;8(14):22811-22824. doi: 10.18632/oncotarget.15206. PMID:
28423558; PMCID: PMC5410264.

52: Pirozzi CJ, Carpenter AB, Waitkus MS, Wang CY, Zhu H, Hansen LJ, Chen LH,
Greer PK, Feng J, Wang Y, Bock CB, Fan P, Spasojevic I, McLendon RE, Bigner DD,
He Y, Yan H. Mutant IDH1 Disrupts the Mouse Subventricular Zone and Alters Brain
Tumor Progression. Mol Cancer Res. 2017 May;15(5):507-520. doi:
10.1158/1541-7786.MCR-16-0485. Epub 2017 Feb 1. PMID: 28148827; PMCID:
PMC5415422.

53: Zhou XW, Wang X, Yang Y, Luo JW, Dong H, Liu YH, Mao Q. Biomarkers related
with seizure risk in glioma patients: A systematic review. Clin Neurol
Neurosurg. 2016 Dec;151:113-119. doi: 10.1016/j.clineuro.2016.10.001. Epub 2016
Nov 2. PMID: 27821299.

54: Packer RJ, Pfister S, Bouffet E, Avery R, Bandopadhayay P, Bornhorst M,
Bowers DC, Ellison D, Fangusaro J, Foreman N, Fouladi M, Gajjar A, Haas-Kogan D,
Hawkins C, Ho CY, Hwang E, Jabado N, Kilburn LB, Lassaletta A, Ligon KL,
Massimino M, Meeteren SV, Mueller S, Nicolaides T, Perilongo G, Tabori U, Vezina
G, Warren K, Witt O, Zhu Y, Jones DT, Kieran M. Pediatric low-grade gliomas:
implications of the biologic era. Neuro Oncol. 2017 Jun 1;19(6):750-761. doi:
10.1093/neuonc/now209. PMID: 27683733; PMCID: PMC5464436.

55: Narayanappa R, Rout P, Aithal MG, Chand AK. Aberrant expression of Notch1,
HES1, and DTX1 genes in glioblastoma formalin-fixed paraffin-embedded tissues.
Tumour Biol. 2016 May;37(5):6935-42. doi: 10.1007/s13277-015-4592-7. Epub 2015
Dec 11. PMID: 26662803.

56: Sloan AE, Okada H, Ryken TC, Kalkanis SN, Olson JJ. The role of emerging
therapy in the management of patients with diffuse Low-grade glioma. J
Neurooncol. 2015 Dec;125(3):631-5. doi: 10.1007/s11060-015-1865-3. Epub 2015 Nov
3. PMID: 26530260.

57: Johnson J, Ascierto ML, Mittal S, Newsome D, Kang L, Briggs M, Tanner K,
Marincola FM, Berens ME, Vande Woude GF, Xie Q. Genomic profiling of a
Hepatocyte growth factor-dependent signature for MET-targeted therapy in
glioblastoma. J Transl Med. 2015 Sep 17;13:306. doi: 10.1186/s12967-015-0667-x.
PMID: 26381735; PMCID: PMC4574608.

58: Qiu X, Ji B, Yang L, Huang Q, Shi W, Ding Z, He X, Ban N, Fan S, Zhang J,
Tian Y. The role of FoxJ2 in the migration of human glioma cells. Pathol Res
Pract. 2015 May;211(5):389-97. doi: 10.1016/j.prp.2015.01.005. Epub 2015 Jan 21.
PMID: 25661068.

59: Demetriades AK, Almeida AC, Bhangoo RS, Barrington SF. Applications of
positron emission tomography in neuro-oncology: a clinical approach. Surgeon.
2014 Jun;12(3):148-57. doi: 10.1016/j.surge.2013.12.001. Epub 2014 Mar 11. PMID:
24629841.

60: Griguer CE, Cantor AB, Fathallah-Shaykh HM, Gillespie GY, Gordon AS, Markert
JM, Radovanovic I, Clement-Schatlo V, Shannon CN, Oliva CR. Prognostic relevance
of cytochrome C oxidase in primary glioblastoma multiforme. PLoS One. 2013 Apr
10;8(4):e61035. doi: 10.1371/journal.pone.0061035. PMID: 23593382; PMCID:
PMC3622606.

61: Huang H, Xiang Y, Su B, Xiong W, Zhang X. Potential roles for Gfi1 in the
pathogenesis and proliferation of glioma. Med Hypotheses. 2013 May;80(5):629-32.
doi: 10.1016/j.mehy.2013.02.007. Epub 2013 Mar 5. PMID: 23466061.

62: Xu T, Qin R, Zhou J, Yan Y, Lu Y, Zhang X, Fu D, Lv Z, Li W, Xia C, Hu G,
Ding X, Chen J. High bone sialoprotein (BSP) expression correlates with
increased tumor grade and predicts a poorer prognosis of high-grade glioma
patients. PLoS One. 2012;7(10):e48415. doi: 10.1371/journal.pone.0048415. Epub
2012 Oct 31. PMID: 23119009; PMCID: PMC3485236.

63: Yan W, Zhang W, You G, Zhang J, Han L, Bao Z, Wang Y, Liu Y, Jiang C, Kang
C, You Y, Jiang T. Molecular classification of gliomas based on whole genome
gene expression: a systematic report of 225 samples from the Chinese Glioma
Cooperative Group. Neuro Oncol. 2012 Dec;14(12):1432-40. doi:
10.1093/neuonc/nos263. Epub 2012 Oct 22. PMID: 23090983; PMCID: PMC3499016.

64: Zhang JJ, Weng RG, Liu J, Chen HP, Liu J, Ye H, Zheng WM. [Targeted therapy
of malignant glioma by a chimeric fusion toxin composed of IL-13 and Pseudomonas
exotoxin in vitro]. Zhonghua Yi Xue Za Zhi. 2012 Mar 20;92(11):731-4. Chinese.
PMID: 22781350.

65: Larysz D, Kula D, Kowal M, Rudnik A, Jarząb M, Blamek S, Bierzyńska-Macyszyn
G, Kowalska M, Bażowski P, Jarząb B. Epidermal growth factor receptor gene
expression in High-grade gliomas. Folia Neuropathol. 2011;49(1):28-38. PMID:
21455841.

66: Karsy M, Albert L, Tobias ME, Murali R, Jhanwar-Uniyal M. All-trans retinoic
acid modulates cancer stem cells of glioblastoma multiforme in an MAPK-dependent
manner. Anticancer Res. 2010 Dec;30(12):4915-20. PMID: 21187470.

67: Wagemakers M, Sie M, Hoving EW, Molema G, de Bont ES, den Dunnen WF. Tumor
vessel biology in pediatric intracranial ependymoma. J Neurosurg Pediatr. 2010
Apr;5(4):335-41. doi: 10.3171/2009.11.PEDS09260. PMID: 20367336.

68: Ye F, Gao Q, Cai MJ. Therapeutic targeting of EGFR in malignant gliomas.
Expert Opin Ther Targets. 2010 Mar;14(3):303-16. doi: 10.1517/14728221003598948.
PMID: 20148717.

69: Hargrave D. Paediatric high and Low-grade glioma: the impact of tumour
biology on current and future therapy. Br J Neurosurg. 2009 Aug;23(4):351-63.
doi: 10.1080/02688690903158809. PMID: 19637006.

70: Ohba S, Hirose Y, Yoshida K, Yazaki T, Kawase T. Inhibition of 90-kD heat
shock protein potentiates the cytotoxicity of chemotherapeutic agents in human
glioma cells. J Neurosurg. 2010 Jan;112(1):33-42. doi: 10.3171/2009.3.JNS081146.
PMID: 19408974.

71: Sawamura Y, de Tribolet N. [[Immunobiology]] of brain tumors. Adv Tech Stand
Neurosurg. 1990;17:3-64. doi: 10.1007/978-3-7091-6925-4_1. PMID: 2180410.